These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 21565595)

  • 21. Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study.
    Frodl T; Scheuerecker J; Schoepf V; Linn J; Koutsouleris N; Bokde AL; Hampel H; Möller HJ; Brückmann H; Wiesmann M; Meisenzahl E
    J Clin Psychiatry; 2011 Apr; 72(4):448-57. PubMed ID: 20868630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venlafaxine in the treatment of children and adolescents with major depression.
    Mandoki MW; Tapia MR; Tapia MA; Sumner GS; Parker JL
    Psychopharmacol Bull; 1997; 33(1):149-54. PubMed ID: 9133767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
    Hwang JP; Yang CH; Tsai SJ
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):189-90. PubMed ID: 14758586
    [No Abstract]   [Full Text] [Related]  

  • 24. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial.
    Kang EH; Lee IS; Chung SK; Lee SY; Kim EJ; Hong JP; Oh KS; Woo JM; Kim S; Park JE; Yu BH
    Psychiatry Res; 2009 Sep; 169(2):118-23. PubMed ID: 19695711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of major depression: is improvement enough?
    Ferrier IN
    J Clin Psychiatry; 1999; 60 Suppl 6():10-4. PubMed ID: 10235119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
    Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic action lag time and resistance to treatment].
    Peretti CS
    Encephale; 1999 Jun; 25 Spec No 2():49-54. PubMed ID: 10434159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
    Malhi GS; Ng F; Berk M
    Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the antidepressant effects of venlafaxine and dosulepin in a naturalistic setting.
    Bukh JD; Jørgensen MB; Dam H; Plenge P
    Nord J Psychiatry; 2009; 63(4):347-51. PubMed ID: 19347769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.
    Plesnicar BK
    Psychiatr Danub; 2010 Sep; 22(3):413-7. PubMed ID: 20856184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
    Sheehan DV
    J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose venlafaxine in delusional and severely depressed patients.
    Ruiz-Doblado S; Rueda-Villar T; Casillas-Lara L
    J Psychopharmacol; 2009 Sep; 23(7):859-60. PubMed ID: 18562440
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of narcolepsy with cataplexy.
    Plazzi G; Montagna P; Provini F; Albani F; Riva R
    Lancet; 2007 Mar; 369(9567):1081. PubMed ID: 17398305
    [No Abstract]   [Full Text] [Related]  

  • 37. [Correction of affective disorders in patients with cochlear-vestibular disturbances of vascular origin].
    Kunel'skaia NL; Umarova KhIa; Gulieva AE; Chugunov AV; Kamchatnov PR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):81-3. PubMed ID: 18567196
    [No Abstract]   [Full Text] [Related]  

  • 38. Low-dose-trazodone-induced disorganized type psychosis.
    Mizoguchi Y; Monji A
    J Neuropsychiatry Clin Neurosci; 2005; 17(2):253-4. PubMed ID: 15939985
    [No Abstract]   [Full Text] [Related]  

  • 39. Compassion in Spanish-speaking health care: A systematic review.
    Salvador Zaragozá A; Soto-Rubio A; Lacomba-Trejo L; Valero-Moreno S; Pérez-Marín M
    Curr Psychol; 2023; 42(8):6732-6751. PubMed ID: 34220172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mindfulness-Based Program Plus Amygdala and Insula Retraining (MAIR) for the Treatment of Women with Fibromyalgia: A Pilot Randomized Controlled Trial.
    Sanabria-Mazo JP; Montero-Marin J; Feliu-Soler A; Gasión V; Navarro-Gil M; Morillo-Sarto H; Colomer-Carbonell A; Borràs X; Tops M; Luciano JV; García-Campayo J
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.